Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Khot

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|September 7, 2022
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphomaLeisa R Watson, Thomas E Lew, Lucy C Fox, et al.
Leukemia & Lymphoma|October 9, 2010
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathyRebecca Howman, Arti Thakerer, Matthew Pitman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2021
Advances in Frontline Management of Peripheral T-cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Cancers|October 29, 2020
Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 5, 2021
Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centreJessica Crowe, Jill J Francis, Lara Edbrooke, et al.
Blood|September 28, 2011
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous routeClaire E Dearden, Amit Khot, Monica Else, et al.
Internal Medicine Journal|June 20, 2025
A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 yearsRory Bennett, Thomas Frawley, Philip A Thompson, et al.
British Journal of Haematology|November 8, 2025
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases RegistrySueh-Li Lim, Cameron Wellard, Rajeev Rajagopal, et al.
Bone Marrow Transplantation|July 21, 2021
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated diseaseThomas E Lew, Edward R S Cliff, Michael Dickinson, et al.
Expert Review of Hematology|December 22, 2021
The development of a home-based therapeutic platform for multiple myelomaHayley Beer, David Routledge, Trish Joyce, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|September 7, 2022
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphomaLeisa R Watson, Thomas E Lew, Lucy C Fox, et al.
Leukemia & Lymphoma|October 9, 2010
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathyRebecca Howman, Arti Thakerer, Matthew Pitman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2021
Advances in Frontline Management of Peripheral T-cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Cancers|October 29, 2020
Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 5, 2021
Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centreJessica Crowe, Jill J Francis, Lara Edbrooke, et al.
Blood|September 28, 2011
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous routeClaire E Dearden, Amit Khot, Monica Else, et al.
Internal Medicine Journal|June 20, 2025
A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 yearsRory Bennett, Thomas Frawley, Philip A Thompson, et al.
British Journal of Haematology|November 8, 2025
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases RegistrySueh-Li Lim, Cameron Wellard, Rajeev Rajagopal, et al.
Bone Marrow Transplantation|July 21, 2021
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated diseaseThomas E Lew, Edward R S Cliff, Michael Dickinson, et al.
Expert Review of Hematology|December 22, 2021
The development of a home-based therapeutic platform for multiple myelomaHayley Beer, David Routledge, Trish Joyce, et al.
Pageof 7